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A B S T R A C T
Background: Very few randomized controlled trials (RCTs) have compared laparoscopic
Nissen fundoplication (LNF) to proton pump inhibitors (PPI) medical management for pa-
tients with chronic gastroesophageal reflux disease (GERD). Larger RCTs have been rela-
tively short in duration, and have reported mixed results regarding symptom control and
effect on quality of life (QOL). Economic evaluations have reported conflicting results.
Objectives: To determine the incremental cost-utility of LNF versus PPI for treating patients
with chronic and controlled GERD over 3 years from the societal perspective.
Methods: Economic evaluation was conducted alongside a RCT that enrolled 104 patients
from October 2000 to September 2004. Primary study outcome was GERD symptoms (sec-
ondary outcomes included QOL and cost-utility). Resource utilization and QOL data col-
lected at regular follow-up intervals determined incremental cost/QALY gained. Stochastic
uncertainty was assessed using bootstrapping and methodologic assumptions were as-
sessed using sensitivity analysis.
Results: No statistically significant differences in GERD symptom scores, but LNF did result
in fewer heartburn days and improved QOL. Costs were higher for LNF patients by $3205/
patient over 3 years but QOL was also higher as measured by either QOL instrument. Based
on total costs, incremental cost-utility of LNF was $29,404/QALY gained using the Health
Utility Index 3. Cost-utility results were sensitive to the utility instrument used ($29,404/
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264 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 6 3 – 2 7 3QALY for Health Utility Index 3, $31,117/QALY for the Short Form 6D, and $76,310/QALY for
EuroQol 5D) and if current lower prices for PPIs were used in the analysis.
Conclusions: Results varied depending on resource use/costs included in the analysis, the
QOL instrument used, and the cost of PPIs; however, LNF was generally found to be a
cost-effective treatment for patients with symptomatic controlled GERD requiring long-
term management.
Copyright © 2011, International Society for Pharmacoeconomics and Outcomes Research(ISPOR). Published by Elsevier Inc.1. Introduction
Gastroesophageal reflux disease (GERD) is a common disorder
managed by both family physicians and specialists. Affecting
up to 30% of the developed world [1,2], patients with GERD
exhibit a full spectrum of symptoms varying frommild, which
require little medical attention, to severe, which requires con-
tinuous medication therapy, diagnostic investigations, and
perhaps corrective surgery. It is in the intermediate symptom
group where GERD treatment is most prevalent and which
imposes the largest impact on the health care system. In the
United States in 2002, GERD was the most common reason for
visits to physicians (more than 5 million visits) for gastroin-
testinal disorders [3], and as a result GERDwas a costly disease
costing more than $10 billion [4]. In Canada, more than
CDN$670 million is spent on proton pump inhibitor (PPI) and
histamine-2 receptor antagonist (H2RA) therapy each year [5].
GERD can also have a large affect on health-related quality of
life (QOL) by disrupting sleep, diet patterns, and workplace
productivity. For example, studies have shown QOL is statis-
tically significantly lower in GERD patients compared to non-
GERD populations [6,7].
Goals of GERD treatment are to resolve symptoms, heal the
esophagitis, prevent recurrences, and prevent complications
such as stricture, Barrett’s esophagus, and bleeding [8]. Pa-
tients with frequent and severe symptoms, particularly if they
are associated with moderate or severe esophagitis, generally
need long-term maintenance therapy. Treatment of patients
with GERD includes medical and surgical therapies that have
varying success rates. There are two general classes of medi-
cal therapy for acid suppression: H2RAs and PPIs. PPIs have
een proven to be more effective in symptom resolution and
ealing of the esophagitis is quicker and more reliably
chieved with PPIs across all grades of GERD severity [9]. In
ddition, almost all economic evaluations comparing H2RAs
to PPIs for patients with symptomatic GERD have found that
on-demand (i.e., taken as needed) PPIs are less costly and
more effective than H2RAs for mild to severe GERD [10].
Despite studies reporting varying effectiveness for PPIs
(80–95%), it has also been demonstrated that up to 50% of
patients continue to experience abnormal esophageal acid ex-
posure on 24-hour pH testing [11] and up to 37% experience a
relapse of symptoms within 5 years of treatment [12]. An al-
ternative to long-term medical therapy with PPIs is open or
laparoscopic Nissen fundoplication (LNF) surgery. Although
both surgical approaches are equally effective in controlling
reflux, the open technique is associated with longer hospital-
ization and significantly higher rates of wound and respira-tory complications [13]. In addition to shorter hospitalization,
LNF can reduce hospital costs and can result in faster return to
work and normal activities than open surgery [14]. It has also
been shown that LNF can result in significant improvements
in QOL over open surgery in a number of domains [15] and,
therefore LNF has emerged as the gold standard for surgical
treatment of GERD patients [16,17].
Whereas medical therapies provide symptom relief, the
aim of surgery is to correct the underlying physiological defect
[18]. In a systematic review comparing medical therapy with
LNF, the authors found that surgically treated patients expe-
rienced significantly less esophageal acid exposure; however,
there were insufficient data to determine whether LNF was
superior for maintaining healing of esophagitis or in reducing
the incidence of Barrett’s esophagus or esophageal adenocar-
cinoma [19]. Unfortunately, there have been few randomized
controlled trials (RCTs) comparing LNF to PPIs for treating pa-
tients with chronic GERD. The UK REFLUX trial found that LNF
resulted in improved reflux, QOL, EuroQol 5 Dimmensions
(EQ5D), and well-being scores compared to PPIs at 1 year
[20,21]. The Nordic GORD Study Group found that LNF im-
proved rates of symptomatic recurrence but did not find dif-
ferences in QOL compared to PPIs at 3 [22], 5 [12], or 12 years
[23] of patient follow-up. And finally, interim analysis of the
LOTUS trial found improvedQOLwith LNF but no difference in
recurrence rates compared to PPIs at 3 years of follow-up [24].
Clearly the RCT evidence to date has reported mixed results
with respect to symptom control, rate of recurrence, and af-
fect on patient QOL.
Similarly, economic evaluation studies have reported
mixed results comparing the two types of therapy. There has
been one trial-based economic evaluation based on the
REFLUX trial, which reported LNF to be very cost-effective at 1
year [2]. Modeling study results have varied from PPIs dom-
inating LNF [25], to PPIs beingmore effective but more costly
than LNF [26], to LNF being more effective and more costly
but not considered to be cost-effective [27,28], to LNF being
more effective and more costly and considered to be cost-
effective [29,30].
Given the paucity of RCT data comparing LNF to PPIs and in
light of the mixed clinical results from the existing trial data
on remission rates and affect on QOL, additional comparative
trial data is needed to help determine the clinical effective-
ness and affect on patient QOL of LNF compared to PPI man-
agement. In addition, because most of the existing RCTs are
relatively short in duration (i.e., 1 year), the longer-term effec-
tiveness of LNF has not been adequately explored with exist-
ing trials. For example, one of the proposed benefits of LNF
surgery is the reduction in future drug use, doctor visits, and
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265V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 6 3 – 2 7 3investigative testing. However, 1 year of patient follow-up, like
in the two UK RCTs [20,21], may be too short to adequately
capture these benefits or determine if the observed short-term
benefits from LNF surgery are maintained over longer periods
of time. Another concernwith some of the existing trial data is
that GERD patients are recruited from specialist centers and a
number of these patients are referred to specialists because
their GERD symptoms are uncontrolled with PPI treatment. A
trial that focuses specifically on chronic and controlled GERD
patients would address the effectiveness of LNF in patients
who are managed primarily by a family physician. Finally,
given the wide variation in reported economic evaluation re-
sults, the paucity of trial-based economic evaluations that are
based on actual patient data as opposed to modeling assump-
tions, and the absence of any trial-based economic evalua-
tions in Canada, the purpose of this study was to determine
the incremental cost-effectiveness (specifically cost-utility) of
LNF compared to PPI for the treatment of patients with
chronic and controlled GERD over a 3-year time period from a
societal perspective based on a RCT in an experienced Cana-
dian center.
2. Methods
2.1. Overview of the trial
A detailed description of the study design and 1-year clinical
outcomes have been previously reported [31]; however, a brief
overview is provided here. BetweenOctober 2000 and Septem-
ber 2004, patients with GERD who were stable and symptom-
atically controlled on long-term medical therapy were re-
cruited into a two-arm, parallel, non-blinded prospective RCT.
Patients were recruited from a GERD clinic run by one of the
principal investigators (MA) in a tertiary level teaching hospi-
tal in Hamilton, ON, Canada. Patients were referred to the
clinic for diagnosis and management by family physicians,
gastroenterologists, general surgeons, pulmonologists, otolar-
yngologists, allergists, and internists. Patients recruited into
the study had to be between age 18 and 70 years, were re-
quired to have had prior long-term (minimum 1 year) treat-
ment with a PPI, were required to be controlled on medical
therapy, and were required to have chronic symptoms of
GERD necessitating long-term therapy anticipated to last at
least another 2 years.
2.2. Interventions
Patients were randomized to receive either PPI therapy or LNF
plusmedication therapy as needed.Medically treated patients
received the same PPI dose they received before the trial to
control their symptoms. Patients’ symptomswere assessed at
baseline using a symptom visual analogue scale (VAS) and a
disease-specific gastroesophageal reflux disease symptom
scale (GERSS) [32] and if a patient’s symptoms were poorly
controlled, medical therapy was adjusted until symptoms
were controlled. For patients randomized to surgery, the LNF
was performed by one of four laparoscopic surgeons, each
with experience on more than 50 cases, and each using their eown preferredmethod of wrap. Surgery patients also received
medications as needed to control their GERD symptoms.
2.3. Primary and secondary clinical outcomes
The primary clinical outcomes were reflux symptoms mea-
sured using the GERSS [32] and heartburn (HB)-free days based
on the week before regular assessment visits. Secondary clin-
ical outcome measures included esophageal function, gas-
troscopy, 24-hour pH, esophageal manometry, and patient
symptom control using a VAS score.
2.4. Economic evaluation—resource use and costs
In addition to clinical outcomes, resource use and QOL data
were collected on each patient every 3 months for 3 years.
Costing was conducted from a societal perspective. Resource
use collected included: emergency room visits, hospitaliza-
tions, family physician visits, specialist visits, clinic visits,
other health care professional visits, tests, procedures, surger-
ies, and prescription and over-the-counter medications (by
drug name and dosage as reported in the patient expense log).
Productivity loss information was also collected. The base
case analysis included all costs, but in a sensitivity analysis
costs were restricted only to those that patients self-reported
were attributable to GERD. For costs such as emergency room
visits and hospitalizations, the attribution to GERD was de-
termined by clinical opinion and review of medical records.
Productivity losses were estimated separately as days lost
from paid employment for the patient or caregiver, days lost
from homemaking activities, and days lost from volunteer
activities.
Unit prices used in the analysis came fromvarious sources.
Professional fees were obtained from the Ontario Schedule of
Benefits for physician services [33]; other professional fees
(e.g., acupuncturist, massage therapy) were obtained through
a survey of local commercial providers. Clinic visit costs, lab-
oratory and procedure costs, emergency room visits, and hos-
pitalization costs were obtained from a hospital participating
in the Ontario Case Costing Initiative [34] and the appropriate
professional fee code came from the Ontario Schedule of Ben-
efits [33]. Over-the-counter medication costs were obtained
from a survey of local retail pharmacies; prescription medica-
tion costs were obtained from the Ontario Drug Benefit For-
mulary Plan [35] alongwith a pharmacymark-up allowance of
8% [36] and average dispensing fees were obtained from a sur-
ey of retailers [37]. Productivity losses were valued using av-
rage hourly wages from Statistics Canada [38]. As there were
large number of drug/dosage combinations, tests and proce-
ures, and hospitalizations reported in the patient case report
orms, only selected unit costs used in the analysis are pre-
ented in Table 1. All costs are expressed in 2009 Canadian
ollars and costs in years 2 and 3 were discounted at 5% in the
ase case analysis. As a result of recent changes in drug prices
n Ontario in July 2010, an additional set of analyses was con-
ucted using 2010 drug prices for the main analysis and for
ach analysis based on key methodologic assumptions.
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valuation
Utility values were estimated based on QOL questionnaires
administered at baseline and every 3 months. Although the
Health Utility Index 3 (HUI3) was identified as the primary
utility measure for the economic evaluation, for comparative
purposes Short Form 6D (SF6D) and EQ5D scores were also
collected on each patient over time for use in a sensitivity
analysis. The HUI3 was used as the primary QOL instrument
because of the popularity of the HUI3 in Canada and because
this instrument is themost sensitive in terms of attributes and
levels. The SF6D was administered every 3 months and the
EQ5D annually. Average treatment group utility scores were
estimated at each time point and treatment group utility pro-
files were estimated over time based on linear interpolation
between assessment intervals. Three-year quality-adjusted
life years (QALY) estimates were calculated as the area under
the utility curve for each patient and treatment group. Despite
randomization, average utility scores at baseline were not
equivalent between treatment groups, and differences in
QALYs across the 3-year period were therefore estimated as
the difference in mean QALYs between the two treatment
groups adjusted for baseline differences [39].
Dominance (i.e., whether one treatment was superior on
both costs and effects) was first assessed and in the case of a
trade-off between higher costs and improved QOL with LNF,
an incremental cost-utility ratio (ICUR) was calculated as the
ratio of the incremental cost of LNF divided by incremental
Table 1 – Selected unit costs by type of resource, 2009 Can
Resource Un
(2010 drug prices f
Specialist consult $
Specialist follow-up visit
Family physician visit
Physiotherapy
Chiropractor visit
Massage therapy
Walk-in clinic visit
Nutrition clinic
Emergency room visit $
LNF surgery cost per day $2
LNF redo surgery cost per day $1
Bowel Obstruction cost per day $1
Chest pain care cost per day $
Chest Inflammation cost per day $
CBC
Helicobacter pylori $15.5
Upper GI series $79.9
PPI – Omeprazole 20 mg $1.1
PPI – Pantoprazole 40 mg $1.9
PPI – Rabeprazole 20 mg $1.3
PPI – Lansoprazole 15 mg $2.0
Rantidine 150 mg $0.4
Average hourly wage
SoB, schedule of benefits; OCCI, Ontario Case Costing Initiative; DBF
inhibitor; LNF, laparoscopic Nissen fundoplication.QALYs (i.e., incremental cost per QALY gained). In sensitivityanalyses, the ICUR calculation was repeated using the SF6D
and EQ5D utility scores. If dominance occurred, average costs
and effectiveness were reported and an ICUR was not calcu-
lated. As with costs, effectiveness in years 2 and 3 were dis-
counted at 5% per year in the base case analysis.
2.6. Data analysis for missing and censored data
For patientswith incomplete costs or QOL questionnaires dur-
ing the 3-year follow-up period (i.e., those who withdrew, [for
PPI n 3, for LNFn 2], were lost to follow-up [for PPI n 3, for
LNF n  0], or missed intermittent assessments), any missing
information was estimated using multiple imputation. Hot-
deck multivariate normal switching regression multiple im-
putation [40] was implemented using all available data from
all patients as potential covariates. Covariates included age,
sex, smoking status, presence of cardiac history, design block,
as well as health status (individual HUI3, SF6D, and EQ5D
overall scores) and costs (individual GERD and non-GERD
costs) from all available past and subsequent visits. On each
occasion, 10 imputations were obtained using STATA SE ver-
sion 9.2 [41] and the imputationswere averaged for estimating
the missing information.
2.7. Stochastic uncertainty and sensitivity analyses
Following imputations for any missing information, the esti-
mated cost and outcome data for each patient were used for
assessing stochastic uncertainty by estimating 1000 boot-
dollars.
st
nsitivity analysis)
Source
0 Ontario SoB
0 Ontario SoB
0 Ontario SoB
0 Ontario SoB
0 Ontario Chiropractic Association
0 Survey of local commercial rates
7 OCCI
0 Survey of local commercial rates
(initial visit/assessment)
0 OCCI
0 OCCI
0 OCCI
0 OCCI
0 OCCI
0 OCCI
7 OCCI
1.70 Ontario SoB, OCCI
8.53 Ontario SoB, OCCI
55) Ontario DBF
51) Ontario DBF
33) Ontario DBF
50) Ontario DBF
30) Ontario DBF
7 Statistics Canada
g Benefit Formulary; CBC, complete blood count; PPI, proton pumpadian
it co
or se
132.5
$82.9
$56.1
$24.4
$77.0
$50.0
$60.7
$80.0
246.0
340.0
279.0
489.0
995.0
843.0
$8.2
1  $2
6  $9
0 ($0.
0 ($0.
0 ($0.
0 ($0.
0 ($0.
$21.8
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sults were plotted on the cost-effectiveness plane. Cost-
effectiveness acceptability curves (CEACs) were calculated
showing the probability of LNF being more cost-effective than
PPI as a function of society’s willingness-to-pay (WTP) for a
QALY gained. For assessing methodological uncertainty, de-
terministic sensitivity analyses were conducted. Assessed
were alternative discount rate assumptions (5% vs. 0% and
10%), different cost perspectives (society vs. third-party
payer), inclusion of different resource use items (all costs vs.
self-assessed GERD-related only), and different instruments
for assessing utility (HUI3 vs. SF6D and EQ5D). Two sets of
sensitivity analyses are provided, one with 2009 prices for
drugs and an additional analysis with 2010 prices for drugs.
2.8. Statistical analyses
Resource use data are presented as counts and percentages,
whereas continuous cost and utility variables are presented as
means SD. Differences in counts for resource usewere com-
ared using chi-squared tests. Because costs and QOL esti-
ates tend to be skewed, these variables were fitted using
amma distributions and arithmetic means were compared
cross groups. CEACs are typically interpreted as the probabil-
ty (based on stochastic uncertainty) that one treatment has a
igher probability of being cost-effective at a given WTP
hreshold. As CEACs are based on expectations, no statistical
nalyses are conducted on these results.
3. Results
Of the 1666 patients screened for the study, 180 were eligible
for randomization and 104 agreed to participate in the study.
Baseline demographics of the study participants have been
reported elsewhere and were comparable between the two
treatment groups with 53% beingmen andwith amean age of
42 years [31]. Of the 104 patients randomized (52 to each
roup), two PPI patients and one LNF patient withdrew from
he study immediately and 93 patients were available for the
Table 2 – Selected resource use over 3 years of follow-up (p
Resource use Total
PPI (n  52) LNF (n  52
LNF or repeat LNF 11 (15) 58 (98)
Other hospitalizations 15 (14) 12 (15)
Emergency room visits 60 (63) 74 (62)
Family physician visits 567 (90) 441 (94)
Specialist visits 239 (88) 317 (96)
Clinic visits 32 (38) 51 (44)
Other HC professionals 955 (65) 934 (54)
Productivity hours lost 20.4 (69) 37.7 (79)
Normal activity hours lost 41.4 (69) 29.0 (75)
Total† 61.7 (88) 66.7 (92)
PPI, proton pump inhibitor; LNF, laparoscopic Nissen fundoplication;
* Does not include multiple imputations.
† Note that totals may not equal sums due to rounding.ull 3-year follow-up.3.1. Clinical outcomes
In terms of the primary clinical outcome of GERSS, both PPI
and LNF patients demonstrated improved symptoms over
time, with no statistically significant difference between
groups at 3 years (mean difference 2.66; 95% confidence inter-
val1.11–6.43; P 0.1660). HB-free days and patient symptom
control using a VAS score were significantly better at 3 years
for LNF treated patients (HB days difference1.35; P 0.0077;
nd VAS score difference -10.16; P  0.0093).
3.2. Resource use and costs for study participants
Selected resource use information collected on the 104 pa-
tients during the 3-year follow-up period is presented in
Table 2. Not only are total resources presented, but also shown
are the patient’s attributions of whether they thought these
were related to their GERD condition (i.e., for use in a sensitiv-
ity analysis). Other than hospitalizations for LNF, there were
no differences across groups in terms of other hospitalizations
or emergency roomvisits. As shown inTable 2, the one patient
whowithdrew from the study did not receive LNF, and as such
the percentage of patients receiving LNF is 98%. LNF treated
patients had more total visits to specialists, more clinic visits,
more hours of lost productivity, but fewer family physician
visits and hours lost from normal activity. In terms of GERD-
related resource use, family physician visits (51 vs. 12) and the
use of other health care professionals were lower for LNF-
treated patients (41 vs. 0 visits).
Mean costs by type of expense, year of follow-up, and treat-
ment group are presented in Table 3. Costs by expense cate-
gory and the first set of total cost estimates do not include
multiple imputations for missing or incomplete resource use
and cost information. The total cost estimates at the bottom
on Table 3 include estimates following multiple imputations.
As can be seen from Table 3, the biggest difference in 3-year
costs were related to hospitalizations (i.e., higher for LNF-
treated patients) and medications (i.e., lower for LNF-
treated patients) such that overall costs were $3205 higher
for patients receiving LNF. Considering estimates of GERD-
ntage), by treatment group*.
GERD-related only
P PPI (n  52) LNF (n  52) P
0.001 11 (15) 58 (98) 0.001
0.481 — — —
0.227 23 (25) 29 (21) 0.405
0.001 51 (40) 12 (15) 0.001
0.001 97 (69) 88 (75) 0.508
0.037 3 (6) 4 (6) 0.705
0.629 41 (77) 0 (0) 0.001
0.023 20.4 (69) 37.7 (79) 0.023
0.139 41.4 (69) 29.0 (75) 0.139
0.653 61.7 (88) 66.7 (92) 0.653
ealth care; GERD, gastroesophageal reflux disease.erce
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from Table 3, there was a strong time pattern in costs with
LNF costs higher in year 1 where the surgery occurred and
then decreasing over time to be about $1700 lower in year 3
for total resource use and costs and $1200 lower for GERD-
related costs.
3.3. QoL and utility
Based on patient QOL assessments during the 3-year fol-
low-up period, utility scores by treatment group are presented
in Figure 1 for the HUI3, SF6D, and EQ5D instruments. Al-
though patients in the study were randomized, there were
differences in baseline utility scores, especially for the HUI3
and EQ5D. As can be seen from Figure 1, patients’ QOL im-
proved over time in both treatment groups and this was ob-
served across all three utility instruments. The changes in
QALYs for each treatment group during 3 years based on the
HUI3, and after adjusting for baseline differences, are pre-
sented in Table 4. LNF patients had an area under the curve
improvement of 0.276 compared to PPI patients at 0.167 (mean
difference 0.109; P  0.159). In other words, during the 3-year
eriod LNF patients experienced a 0.109 gain in QALYs com-
ared to PPI patients.
3.4. Cost utility and stochastic uncertainty
Based on an incremental cost of $3205 and gain in QALYs of
0.109 for LNF-treated patients, the base case ICUR for LNF
compared to PPI is $29,404 per QALY gained (Table 4). The
results from the 1000 bootstrap estimates are plotted on the
cost-effectiveness plane in Figure 2, which shows a concen-
ration of uncertainty in the northwest quadrant indicating a
Table 3 – Mean (median) costs per patient, by type of expe
Expense category LNF (n52)
Year 1 ($) Year 2 ($) Yea
Hospitalizations 7710 (4680) 1274 (0) 507
Emergency room visits 164 (0) 138 (0) 100
Family doctor visits 142 (70) 150 (112) 134
Specialist visits 253 (176) 216 (116) 123
Clinic visits 48 (0) 43 (0) 14
Other health care
professionals
169 (0) 198 (0) 191
Lab tests 236 (101) 92 (8) 179
Medications 979 (564) 849 (369) 714
Productivity losses 464 (153) 224 (5) 185
Usual activity losses 335 (153) 235 (0) 128
Total costs* 10499 (8371) 3418 (1083) 2276
GERD-related total costs* 8938 (6630) 655 (165) 549
Imputed total costs† 10326 (8811) 3540 (1908) 2083
Imputed GERD-related
total costs†
8601 (7353) 765 (407) 572
LNF, laparoscopic Nissen fundoplication; PPI, proton pump inhibitor;
* Mean and median costs by expense category and totals across ca
resource se and cost information.
† These total costs and GERD-related total costs include multiple imost and utility trade-off but with a fair amount of this sto- Tchastic uncertainty crossing into all four quadrants of the
cost-effectiveness plane. Through the use of the net-benefit
framework, the CEAC for LNF was calculated and is presented
in Figure 3 for the HUI3 utility scores (small dashed line). The
CEAC shows that for societal WTP values above $30,000 per
QALY gained, LNF has the highest probability of being the
most cost-effective treatment alternative.
3.5. Methodologic uncertainty
Presented in the first panel in Table 5 are the expected costs,
QALYs, and cost-utility results of alternativemethodologic as-
sumptions using 2009 drug prices (i.e., base case year of anal-
ysis). Using SF6D utility scores compared to HUI3 scores had a
minimal influence on QALYs and cost-utility ($29,404 per
QALY gained vs. $31,117 per QALY gained). However, the esti-
mated QALYs gained using the EQ5D scores were less than
half that estimated for the HUI3 or SF6D, and therefore had a
much larger influence on the cost-utility results ($76,310 per
QALY gained). For comparative purposes the CEACs for all
three utility measures are presented in Figure 3. The sensitiv-
ity analysis results in the first panel of Table 5 also show that
using GERD-related costs only, or adopting a third-party payer
perspective and using alternative discount rate assumptions
(0% and 10%) did not have a substantial influence on the cost-
utility results. The second panel of Table 5 presents sensi-
ivity analysis results that reflect recent drug price changes
or 2010. As can be seen from Table 5, the cost-utility results
ncrease for the base case analysis (i.e., $43,422 per QALY
ained) and all other sensitivity analysis variants. When
sing 2010 drug prices, most of the cost-utility results in-
reased approximately $13,000 to $15,000 per QALY gained.
year of follow-up and treatment group*.
PPI (n52) 3 year
difference,
LNF–PPI ($)) Year 1 ($) Year 2 ($) Year 3 ($)
719 (0) 1618 (0) 1264 (0) 5889
90 (0) 122 (0) 98 (0) 91
199 (148) 225 (105) 187 (105) 184
162 (116) 179 (87) 175 (0) 77
17 (0) 12 (0) 14 (0) 62
412 (0) 161 (0) 272 (8) 287
126 (21) 135 (8) 262 (8) 17
1765 (1136) 1839 (1175) 1813 (1423) 2876
198 (15) 170 (0) 170 (0) 334
372 (29) 216 (0) 173 (0) 63
) 4060 (1962) 4678 (2212) 4429 (2331) 3027
1972 (1175) 2717 (1268) 1983 (1086) 3470
) 4237 (2175) 4730 (2274) 3776 (2326) 3205
1979 (922) 3117 (1195) 1770 (1066) 3073
, Gastroesophageal reflux disease.
ies do not include multiple imputations for missing or incomplete
ions.nse,
r 3 ($
(0)
(0)
(56)
(0)
(0)
(0)
(12)
(96)
(0)
(0)
(1089
(144)
(1308
(365)
GERD
tegorhe exception is the analysis based on EQ5D utility weights,
269V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 6 3 – 2 7 3Fig. 1 – Quality of life scores over time using the Health Utilities Index version 3 (HUI3), Short Form 6 Dimensions (SF6D),
and EuroQOL 5 Dimensions (EQ5D) by treatment group (unadjusted for baseline imbalances).
ion 3.
270 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 6 3 – 2 7 3which increased the cost-utility results to $112,690 per
QALY gained.
4. Discussion
In light of the large expenditures devoted annually to medical
management of patients with GERD and the large affect of
symptoms from this prevalent condition on patient QOL, it is
surprising there is such a paucity of RCT data comparing LNF
and PPI for the management of patients with chronic GERD.
The results from our Canadian study found no difference in
symptoms at 3 years, which is consistent with the LOTUS trial
[24] but in contrast to the REFLUX [20,21] and Nordic GORD
trials [12,22,23] (the latter is a trial comparing open surgery
and not laparoscopic surgery). Our results also found an in-
crease in QOL for LNF-treated patients, which is consistent
with REFLUX [20,21] and LOTUS trials [24], but is in contrast to
the Nordic GORD trial [12,22,23]. Because there is no plausible
explanation for these diverse study findings across jurisdic-
tions, it is clear that more prospective trial-based and long-
term clinical studies are needed to build upon the evidentiary
base of these twomethods ofmanaging gastroesophageal dis-
ease in patients with chronic GERD.
It is similarly difficult to compare the results from this eco-
nomic evaluation to other published health economic studies
due largely to differences in relative prices, differences in
study methods, and differences in treatment effect assump-
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Fig. 2 – Cost-effectiveness stochastic uncertainty results
based on 1,000 bootstrap samples. Proton pump inhibitor
at origin and each dot represents mean incremental cost
and quality-adjusted life year (QALY) for lapasoscopic
Table 4 – Mean costs, quality-adjusted life years (QALYs) a
(LNF) compared to proton pump inhibitor (PPI) treatment.
LNF (
Total costs $15,94
Change in QALYs from baseline (based on HUI3) 0.27
ICUR
Values are mean (SD).
ICUR, incremental cost-utility ratio; HUI3, Health Utilities Index versNissen fundoplication for each simulation.tions. Our results are broadly consistentwith the REFLUX trial-
based economic evaluation [2] and two of themodeling-based
evaluations that found LNF to be cost-effective [29,30]. How-
ever, our results are in contrast to some of the othermodeling-
based evaluations that varied from PPIs being more effective
and more costly than LNF [26], to PPIs dominating LNF [25],
and to LNF being more effective and more costly but not cost-
effective [27,28]. Although some of the differences in results
can be explained by differences in relative prices across juris-
dictions or differences in study methodology (e.g., time hori-
zon), for other studies the differences are largely due to as-
sumptions about the relative effectiveness of PPI versus LNF.
For example, in two of the modeling-based economic evalua-
tions, the authors assumed PPIs would increase QOL com-
pared to LNF [25,26]. Because this assumption is contrary to the
findings fromour study and the other realworld trial-based eco-
nomic evaluation [2] based on actual observed patient follow-up
and measurement, it is not surprising the economic evaluation
results from these studies are quite different.
Our QOL results are strikingly similar to the findings from
the 1-year REFLUX trial-based economic evaluation [2]. Based
on using the EQ5D, Grant et al. [2] found baseline utility values
for their GERD patients to be 0.722, which is identical to our
adjusted EQ5D baseline scores of 0.72. The REFLUX trial re-
ported a difference in QALYs at year 1 of 0.088, which is very
similar to our 1-year difference results and slightly smaller
than our 3-year difference inQALYs of 0.109. This difference at
3 years is to be expected given the slight difference in the QOL
curves that exists over years 2 and 3 before the QOL curves
converge at the end of year 3.
Fig. 3 – Cost-effectiveness acceptability curves. HUI3,
Health Utilities Index version 3. EQ5D, EuroQOL 5
dimensions. SF6D, Short Form 6 Dimensions. WTP,
ost-effectiveness of laparoscopic Nissen fundoplication
2) PPI (n  52) LNF-PPI
81) $12,743 (12,488) $3,205 (16,828)
7) 0.167 (0.589) 0.109 (0.784)
$29,404/QALY gainednd c
n  5
8 (11,2
6 (0.51willingness-to-pay; QALY, quality-adjusted life year.
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271V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 6 3 – 2 7 3Most of the costing studies and economic evaluations that
report longitudinal costs have noted that although LNF is gen-
erally more expensive up front, surgery becomes cost saving
over time as annual costs for surgically managed patients de-
crease whereas costs for medical management remain rela-
tively constant over time. The break-even point in costs has
been found or estimated in some studies to occur around the
second or third year of follow-up [2,26,42]; however, this
reak-even cost has also been estimated to be 8 years [43] and
1 years [28], or even as high as 27 years [25]. A simple extra-
olation of the cost results from our study suggests that the
reak-even cost point for LNF over PPImight be between years
and 5 of study follow-up and this is broadly consistent with
ost other study findings. Given this catching up of cumula-
ive costs of PPIs, it is not surprising that some economic eval-
ations have also reported a decrease in costs per QALY
ained for LNF with longer time horizons. For example, based
n the REFLUX trial, the cost-effectiveness of LNF was esti-
ated at £23,284 per QALY gained at 1 year [2] but £2,648 per
ALY gained with a lifetime perspective [30]. Similarly in the
nited States, the cost-effectiveness of LNF was estimated at
1.65 million per QALY gained at 5 years but $300,000 per
ALY gained at 10 years of follow-up [28]. It is noteworthy that
lthough these studies did find a similar pattern in lower
ncremental cost-effectiveness ratios with a longer time hori-
on, the results from these studies were qualitatively very
ifferent varying from LNF being cost-effective to not being
ost-effective.
There are a number of strengths and limitations of this
tudy that are worthy of mention. One of the major strengths
f this study is that it is a well-conducted prospective RCT in
n experienced center based on actual patient measurement
nd outcomes as opposed to assumptions used in a model.
ther strengths include a relatively long-term study follow-up
eriod (i.e., 3 years), frequent resource use and QOL assess-
Table 5 – One-way sensitivity analysis around key method
Modeling assumption LNF
Costs Q
Analysis based on 2009 drug prices
Base case† $15,948
SF6D utility weights $15,948
EQ5D utility weights $15,948
GERD-related costs only $9,939
3rd party payer perspective $14,070
0% discounting $16,338
10% discounting $15,603
Analysis based on 2010 drug prices
Base case† $16,008
SF6D utility weights $16,008
EQ5D utility weights $16,008
GERD-related costs only $9,706
Third-party payer perspective $14,307
0% discounting $16,414
10% discounting $15,647
LNF, laparoscopic Nissen fundoplication; PPI, proton pump inhibitor; I
Short Form 6 Dimensions; EQ5D, EuroQOL 5 Dimensions.
† Base case uses Health Utilities Index version 3 utility weights, usesent (i.e., every 3months), andQOL corroboration using threeeparate utility-based QOL instruments. One of the limita-
ions of this study is the limited number of patients in the trial
n52 in each arm) as patient recruitment into surgical trials is
otoriously problematic. Another limitation of our study is the
ength of assessment for costs and outcomes because GERD is
chronic condition. Although 3 years is a relatively long fol-
ow-up period for a clinical trial, one of the advantages of a
odeling-based study is the ability to estimate longer-term
ost-effectiveness. Consistent with other longitudinal cost as-
essments, our results suggest that the total cost of LNFmay be
ower than PPI by about 4 to 5 years of treatment and follow-up
nd therefore LNFmaydominate PPI at that time.However, only
longer-term modeling-based study based on these trial costs
nd outcomes would confirm these predictions.
5. Conclusions
We conducted a prospective concurrent RCT and economic
evaluation in 104 patients in an experienced Canadian center
to determine the cost utility of LNF compared to PPI for the
treatment of patients with chronic GERD across a 3-year pe-
riod. Although there was no difference in the primary clinical
GERD symptom score (i.e., GERSS) over 3 years, LNF did result
in fewer HB-free days and improved QOL. At an incremental
cost of $3,205 per patient, LNF cost $29,404 per QALY gained
compared to PPIs and would be considered cost-effective at
WTP thresholds above $30,000 per QALY. LNF was generally
found to be a cost-effective treatment for GERD patients with
the cost-utility results and conclusion somewhat sensitive to
the instrument used to measure QOL (i.e., EQ5D) and the unit
prices for PPIs. LNF was generally found to be a cost-effective
treatment for patients with symptomatic controlled GERD re-
ic assumptions.
PPI ICUR
s Costs QALYs
$12,743 0.167 $ 29,404/QALY
$12,743 0.057 $ 31,117/QALY
$12,743 0.174 $ 76,310/QALY
$6,860 0.167 $ 28,193/QALY
$11,536 0.167 $ 23,248/QALY
$13,366 0.178 $ 26,536/QALY
$12,192 0.157 $ 32,179/QALY
$11,275 0.167 $ 43,422/QALY
$11,275 0.057 $ 46,402/QALY
$11,275 0.174 $112,690/QALY
$5,138 0.167 $ 41,908/QALY
$9,975 0.167 $ 39,743/QALY
$11,829 0.178 $ 40,938/QALY
$10,786 0.157 $ 45,858/QALY
incremental cost-utility ratio; QALY, quality-adjusted life year; SF6D,
costs from a societal perspective, and discounts costs/effects at 5%.olog
ALY
0.276
0.159
0.216
0.276
0.276
0.290
0.263
0.276
0.159
0.216
0.276
0.276
0.290
0.263
CUR,quiring long-term management.
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